BUTYRIC ACID AND INULIN IN THE COMBINATION TREATMENT OF ABDOMINAL PAIN IN IRRITABLE BOWEL SYNDROME
Issue:
10
Year:
2015
The combination of trimebutine and Zacofalc has been shown to surpass that of trimebutine and lactobacteria in efficacy when comparing the magnitude of pain syndrome (p=0.04) and the intensity of painful sensations (p=0.042). The former combination is an effective agent for the therapeutic correction of abdominal pain in patients with irritable bowel syndrome.
Keywords:
irritable bowel syndrome
butyric acid
inulin
References:
- Pimanov S.I., Silivonchik N.N. Rimskij III konsensus: Izbrannye raz- dely i kommentarii / Vitebsk: Izdatel'stvo VGMU, 2006; 160 s.
- Sheptulin A.A. Rimskie kriterii III sindroma razdrazhennogo kishechni ka: chto my ozhidali i chto my uvideli? // RZhGGK. – 2007; 2: 63–8.
- Rey E., Talley N. Irritable bowel syndrome: Novelviews on the epidemiology and potential risk factors // Dig. Liver Dis. – 2009; 41: 772–80.
- Gweek A., Wee S., Wong M. et al. The prevalence, symptom characteristics and impact of irritable bowel syndrome in an Asian urban community // Am. J.. Gastroenterol. – 2004; 99: 924–31.
- Mangel A., Northcutt A. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients // Aliment. Pharmacol. Ther. – 1999; 13 (Suppl. 2): 77–82.
- Ghoshal U., Abraham P., Bhatt C. et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology task force // Indian J. Gastroenterol. – 2008; 27 (1): 22–8.
- Whitehead W., Crowell M., Davidoff A. et al. Pain from rectal distension in women with irritable bowel syndrome // Dig. Dis. Sci. – 1997; 42: 796–804
- Whitehead W., Holtkotter B., Enck P. et al. Tolerance for rectosigmoid distension in irritable bowel syndrome // Gastroenterology. – 1990; 98: 1187–92
- Ardatskaja M.D. Masljanaja kislota i inulin v klinicheskoj praktike: teoreticheskie aspekty i vozmozhnosti klinicheskogo primenenija / M.: Forteprint, 2014; 64 c.
- Banasiewicz T., Kaczmarek E., Maik J. et al. Quality of life andthe clinical symptoms at the patients with irritable bowel syndrometreated complementary with protected sodium butyrate // Gastroenterol. Prakt. – 2011; 5: 45–53.
- Banasiewicz T., Kaczmarek E., Maik J. et al. The influence of protected sodium butyrate on frequency and severity some clinicalsymptoms at the patients with irritable bowel syndrome // Gastroenterol. Prakt. – 2012; 1: 16–23.
- Tarnowski W., Borycka-Kiciak K., Kiciak A. et al. Outcome oftreatment with butyric acid in irritable bowel syndrome – preliminaryreport // Gastroenterol. Prakt. – 2011; 1: 43–8.
- Vanhoutvin S., Troost F., Kilkens T. et al. The effects of butyrate enemas on visceral perception in healthy volunteers // Neurogastroenterol. Motil. – 2009; 21 (9): 952–76.
- Maev I.V., Kucherjavyj Ju.A., Cheremushkin S.V. Evoljutsija predstavlenij o sindrome razrazhennogo kishechnika. Metodicheskie rekomendatsii dlja vra-chej / M., 2013; 80 s.
- Vasil'ev Ju.V. Sindrom razdrazhennogo kishechnika: sovremennye aspekty diagnostiki i terapii // Med. Sovet. – 2014; 4: 72–7.
- Nijevitch A., Akhmadeeva E., Sataev V. et al. Efficacy of Trimebutine Maleate in the Treatment of Functional Dyspepsia in Childhood // J. Nepal. Paediatr. Soc. – 2013; 33 (2): 158–62.
- Delvaux M., Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results // J. Int. Med. Res. – 1997; 25 (5): 225–46
- Lee H., Kim B. Trimebutine as a modulator of gastrointestinal motility // Arch. Pharm. Res. – 2011; 34 (6): 861–4.
- Fioramonti J., Bueno L. Centrally acting agents and visceral sensitivity // Gut. – 2002; 51 (Suppl. 1): 91–5.
- Sarnelli G. Gut microbiota and irritable bowel syndrome: a further link between the big brain – little brain axis // J. Prob. Health. – 2014; 2 (2): 107.
- Lee K., Tack J. Altered intestinal microbiota in irritable bowel syndrome // Neurogastroenterol. Motil. – 2010; 22 (5): 493–8.
- Collins S., Denou E., Verdu E. et al. The putativerole of the intestinal microbiota in the irritable bowel syndrome // Dig. Liver Dis. – 2009; 41 (12): 850–3
- Sudo N., Chida Y., Aiba Y. et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice // J. Physiol. – 2004; 558 (Pt. 1): 263–75.
- Kunze W., Mao Y., Wang B. et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening // J. Cell. Mol. Med. – 2009; 13 (8B): 2261–70.
- Salonen A., de Vos W., Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives // Microbiology. – 2010; 156 (Pt. 11): 3205–15.
- Topping D., Clifton P. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides // Physiol. Rev. – 2001; 81 (3): 1031–64.
- Zaski A., Banaszkiewicz A., Walkowiak J. Butyric acid in irritable bowel syndrome // Prz. Gastroenterol. – 2013; 8 (6): 350–3.
- Guilloteau P., Martin L., Eeckhaut V. et al. From the gut to the peripheral tissues: the multiple effects of butyrate // Nutr. Res. Rev. – 2010; 23 (2): 366–84
- Erofeev N.P., Radchenko V.G., Seliverstov P.V. Klinicheskaja fiziolo gija tolstoj kishki. Mehanizmy dejstvija korotkotsepochechnyh zhirnyh kislot v norme i pri patologii: monografija / SPb: Forte Print, 2012; 56 s.